Heterozygous HTRA1 nonsense or frameshift mutations are pathogenic.


Journal

Brain : a journal of neurology
ISSN: 1460-2156
Titre abrégé: Brain
Pays: England
ID NLM: 0372537

Informations de publication

Date de publication:
22 10 2021
Historique:
received: 25 03 2021
revised: 30 06 2021
accepted: 01 07 2021
pubmed: 17 7 2021
medline: 15 12 2021
entrez: 16 7 2021
Statut: ppublish

Résumé

Heterozygous missense HTRA1 mutations have been associated with an autosomal dominant cerebral small vessel disease (CSVD) whereas the pathogenicity of heterozygous HTRA1 stop codon variants is unclear. We performed a targeted high throughput sequencing of all known CSVD genes, including HTRA1, in 3853 unrelated consecutive CSVD patients referred for molecular diagnosis. The frequency of heterozygous HTRA1 mutations leading to a premature stop codon in this patient cohort was compared with their frequency in large control databases. An analysis of HTRA1 mRNA was performed in several stop codon carrier patients. Clinical and neuroimaging features were characterized in all probands. Twenty unrelated patients carrying a heterozygous HTRA1 variant leading to a premature stop codon were identified. A highly significant difference was observed when comparing our patient cohort with control databases: gnomAD v3.1.1 [P = 3.12 × 10-17, odds ratio (OR) = 21.9], TOPMed freeze 5 (P = 7.6 × 10-18, OR = 27.1) and 1000 Genomes (P = 1.5 × 10-5). Messenger RNA analysis performed in eight patients showed a degradation of the mutated allele strongly suggesting a haploinsufficiency. Clinical and neuroimaging features are similar to those previously reported in heterozygous missense mutation carriers, except for penetrance, which seems lower. Altogether, our findings strongly suggest that heterozygous HTRA1 stop codons are pathogenic through a haploinsufficiency mechanism. Future work will help to estimate their penetrance, an important information for genetic counselling.

Identifiants

pubmed: 34270682
pii: 6322988
doi: 10.1093/brain/awab271
doi:

Substances chimiques

Codon, Nonsense 0
High-Temperature Requirement A Serine Peptidase 1 EC 3.4.21.-
HTRA1 protein, human EC 3.4.21.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2616-2624

Informations de copyright

© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Thibault Coste (T)

AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, France.
Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.

Dominique Hervé (D)

Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.
AP-HP, CERVCO, Service de Neurologie, Hôpital Lariboisière, France.

Jean Philippe Neau (JP)

Centre Hospitalier Universitaire de Poitiers, Service de Neurologie, Poitiers, France.

Eric Jouvent (E)

Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.
AP-HP, CERVCO, Service de Neurologie, Hôpital Lariboisière, France.

Fatoumata Ba (F)

AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, France.

Françoise Bergametti (F)

Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.

Matthias Lamy (M)

Centre Hospitalier Universitaire de Poitiers, Service de Neurologie, Poitiers, France.

Julien Cogez (J)

Centre Hospitalier Universitaire de Caen, Service de Neurologie, Caen, France.

Nathalie Derache (N)

Centre Hospitalier Universitaire de Caen, Service de Neurologie, Caen, France.

Romain Schneckenburger (R)

Centre Hospitalier Universitaire de Caen, Service de Neurologie, Caen, France.

Maude Grelet (M)

Centre Hospitalier Intercommunal de Toulon- La Seyne sur mer, Service de Génétique Médicale, Toulon, France.

Cédric Gollion (C)

Centre Hospitalier Universitaire de Toulouse, Service de Neurologie, Toulouse, France.

Livia Lanotte (L)

Hôpital De Hautepierre, Service de Neurologie, Strasbourg, France.

Valérie Lauer (V)

Hôpital De Hautepierre, Unité Neuro-Vasculaire, Strasbourg, France.

Valérie Layet (V)

Groupe Hospitalier Du havre, Service de Génétique Médicale, Le Havre, France.

Cédric Urbanczyk (C)

Centre Hospitalier Départemental La Roche-Sur-Yon, Service de Neurologie, La Roche-Sur-Yon, France.

Mira Didic (M)

APHM, Hôpital Timone Adultes, Service de Neurologie et Neuropsychologie, Marseille, France.
Aix Marseille Université, INSERM, INS, Inst Neurosci Syst, Marseille, France.

Igor Raynouard (I)

Fondation Adolphe de Rothschild, Service de Neurologie, Paris, France.

Laure Delaval (L)

AP-HP, Hôpital Bichat, Service de Médecine Interne, France.

Jérémie Dassa (J)

Centre Hospitalier Emile Roux, Service de Neurologie, Le Puy-en-Velay, France.

Alexandru Florea (A)

Centre Hospitalier Marie Madeleine, Service de Neurologie, Forbach, France.

Carmen Badiu (C)

Centre Hospitalier Metz-Thionville, Service de Neurologie, Metz, France.

Karine Nguyen (K)

APHM, Hôpital Timone Adultes, Département de Génétique, Marseille, France.

Elisabeth Tournier-Lasserve (E)

AP-HP, Service de Génétique Moléculaire Neurovasculaire, Hôpital Saint-Louis, France.
Université de Paris, INSERM UMR-1141 Neurodiderot, Paris F-75019, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH